CONNECT: an open-label, active-controlled dimethyl fumarate study in pediatric patients with relapsing-remitting multiple sclerosis

被引：0
作者：
Maghzi, A. -H. [1 ]
Levin., S. [1 ]
Alroughani, R. [2 ]
Deiva, K. [3 ,4 ]
Pozzili, C. [5 ]
Lyons, J. [1 ]
Mokliatchouk, O. [1 ]
Pultz, J. [1 ]
N'Dure, F. [1 ]
Liu, S. [1 ]
Badwan, R. [1 ]
Branco, F. [1 ]
Franchimont, N. [1 ]
Hanna, J. [1 ]
Scaramozza, M. [1 ]
Vermersch, P. [6 ]
机构：
[1] Biogen, Cambridge, MA USA
[2] Dasman Diabet Inst, Dasman, Kuwait
[3] Univ Hosp Paris Saclay, Bicetre Hosp, AP HP, Pediat Neurol Dept, Le Kremlin Bicetre, France
[4] French Reference Network Rare Inflammatory Brain, Le Kremlin Bicetre, France
[5] Neurol Ctr Latium, Rome, Italy
[6] Univ Lille, CHU Lille, FHU Precise, INSERM,UMR U 1172, Lille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P095
引用
收藏
页码：194 / 195
页数：2
相关论文
共 50 条
  • [31] Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study
    Kalincik, T.
    Spelman, T.
    Jokubaitis, V.
    Horakova, D.
    Havrdova, E.
    Izquierdo, G.
    Prat, A.
    Girard, M.
    Duquette, P.
    Lugaresi, A.
    Grammond, P.
    Alroughani, R.
    Lechner-Scott, J.
    Prevost, J.
    Terzi, M.
    Grand'Maison, F.
    Boz, C.
    Trojano, M.
    Van Wijmeersch, B.
    Pucci, E.
    Granella, F.
    Turkoglu, R.
    Sola, P.
    Ferraro, D.
    McCombe, P.
    Solaro, C.
    Van Pesch, V.
    Ozakbas, S.
    Slee, M.
    Spitaleri, D.
    Sanchez-Menoyo, J. L.
    Ampapa, R.
    Hodgkinson, S.
    Karabudak, R.
    Vucic, S.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 325 - 327
  • [32] Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
    Eriksson, Irene
    Cars, Thomas
    Piehl, Fredrik
    Malmstrom, Rickard E.
    Wettermark, Bjorn
    von Euler, Mia
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (02) : 219 - 226
  • [33] Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing multiple sclerosis
    Fox, E. J.
    Vasquez, A.
    Grainger, W.
    Ma, T. S.
    von Hehn, C.
    Walsh, J.
    Li, J.
    Zambrano, J.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 205 - 205
  • [34] Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study - REGAIN
    Bayas, Antonios
    Schuh, Katrin
    Baier, Monika
    Vormfelde, Stefan Viktor
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2016, 9 (05) : 378 - 388
  • [35] Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study
    Laura Ordoñez-Boschetti
    Roberto Rey
    Ana Cruz
    Arijit Sinha
    Tracy Reynolds
    Nadina Frider
    Regina Alvarenga
    Advances in Therapy, 2015, 32 : 626 - 635
  • [36] Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
    Irene Eriksson
    Thomas Cars
    Fredrik Piehl
    Rickard E. Malmström
    Björn Wettermark
    Mia von Euler
    European Journal of Clinical Pharmacology, 2018, 74 : 219 - 226
  • [37] Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy
    Laroni, Alice
    Brogi, Davide
    Morra, Vincenzo Brescia
    Guidi, Leonello
    Pozzilli, Carlo
    Comi, Giancarlo
    Lugaresi, Alessandra
    Turrini, Renato
    Raimondi, Debora
    Uccelli, Antonio
    Mancardi, Giovanni Luigi
    NEUROLOGICAL SCIENCES, 2017, 38 (01) : 53 - 59
  • [38] Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy
    Alice Laroni
    Davide Brogi
    Vincenzo Brescia Morra
    Leonello Guidi
    Carlo Pozzilli
    Giancarlo Comi
    Alessandra Lugaresi
    Renato Turrini
    Debora Raimondi
    Antonio Uccelli
    Giovanni Luigi Mancardi
    Neurological Sciences, 2017, 38 : 53 - 59
  • [39] Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
    Ozel, Osman
    Vaughn, Caila B.
    Eckert, Svetlana P.
    Jakimovski, Dejan
    Lizarraga, Alexis A.
    Weinstock-Guttman, Bianca
    PATIENT-RELATED OUTCOME MEASURES, 2019, 10 : 373 - 384
  • [40] Early versus delayed initiation of fingolimod or dimethyl fumarate in relapsing-remitting multiple sclerosis
    Lorscheider, J.
    Schadelin, S.
    Benkert, P.
    Lienert, C.
    Hanni, P.
    Derfuss, T.
    Decard, B.
    Kuhle, J.
    Kappos, L.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 257 - 258
12345